← All trials
NCT04832607
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2019
- Primary completion
- May 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 6, 2021
- Last posted
- Jun 15, 2021
- Enrollment
- 149
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Ghent UniversityCollaborator
- Newcastle UniversityCollaborator
- Leiden UniversityCollaborator
- Ludwig Maximilians UniversityOverall official - principal investigator
- University of LorraineCollaborator
- Bambino Gesù Hospital and Research InstituteCollaborator
- European CommissionCollaborator
- Miltenyi Biotec, Inc.Collaborator
- Ludwig Maximilians UniversitySponsor investigator
- Simbec-OrionCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.